Preferences and perceptions of 617 migraine patients on acute and preventive migraine treatment attributes and clinical trial endpoints.

Autor:	Vikelis M; Mediterraneo Hospital Headache Clinic, Glyfada, Greece.; Greek Society of Migraine and Headache Patients, Athens, Greece., Rikos D; 404 Military Hospital, Headache Clinic, Larissa, Greece., Argyriou AA; Neurology Clinic, Patras General Hospital Agios Andreas, Patras, Greece., Papachristou P; Agrinio Neurology Clinic, Agrinio, Greece., Rallis D; Neurology Clinic, Peripheral General Hospital Tzaneio, Peiraias, Greece., Karapanayiotides T; 2nd Department of Neurology, University General Hospital of Thessaloniki AHEPA Medicine Sector, Thessaloniki, Greece., Galanopoulos A; Neurology Clinic, Pallini, Greece., Spingos K; Corfu Headache Clinic, Corfu, Greece., Dimisianos N; General Neurology Clinic, Corfu, Greece., Giakoumakis E; NeuroCrete Neurology Clinic, Heraklion, Greece., Zavridis P; Headache Clinic, Cyprus Pain Clinic, Nicosia, Cyprus., Notas K; 1st Department of Neurology, University General Hospital of Thessaloniki AHEPA Medicine Sector, Thessaloniki, Greece., Vlachos GS; Mediterraneo Hospital Headache Clinic, Glyfada, Greece., Soldatos P; Kalamata Headache Clinic, Kalamata, Greece., Bilias K; Greek Society of Migraine and Headache Patients, Athens, Greece., Xiromerisiou G; Neurology Clinic, University of Thessaly Faculty of Medicine, Larissa, Greece., Rudolf J; Neurology Department, General Hospital of Thessaloniki Papageorgiou, Thessaloniki, Greece., Dermitzakis EV; Neurology Clinic, Geniki Kliniki Thessalonikis, Thessaloniki, Greece., Rapoport AM; Department of Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Jazyk:	angličtina
Zdroj:	Expert review of neurotherapeutics [Expert Rev Neurother] 2024 Aug; Vol. 24 (8), pp. 815-826. Date of Electronic Publication: 2024 Jun 13.
DOI:	10.1080/14737175.2024.2365312
Abstrakt:	Background: To identify the preferences and perceptions of migraine patients for acute and preventive treatment options and to investigate which treatment outcomes are the most important. Design and Methods: The authors performed a choice-format survey in a cohort of migraine patients from Greece and Cyprus. A self-administered questionnaire developed in collaboration with the Greek Society of Migraine Patients was used. Results: Questionnaires were collected from 617 migraine patients. Efficacy was preferred over safety as the single most important parameter, both in acute and preventive treatment. When analyzing single outcomes, patients prioritized a complete pain remission at 1-hour post-dose for acute therapies. Regarding migraine prevention, a 75% reduction in frequency, intensity of pain, accompanying symptoms and acute medication intake were considered as most important. Conversely, outcomes routinely used in clinical trials, namely complete or partial pain remission at 2-hours post-dose for acute treatment and 50% or 30% reduction in migraine frequency for prevention, were not deemed particularly relevant. Tablet formulation was mostly preferred, both in acute and preventive treatment. Conclusion: Listening to patients' needs may add a piece of the puzzle that is generally missing in clinical practice and often explains the lack of adherence in both acute and preventative anti-migraine therapies.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu